stoxline Quote Chart Rank Option Currency Glossary
  
Organon & Co. (OGN)
11.12  0.3 (2.77%)    04-17 16:00
Open: 10.96
High: 11.22
Volume: 2,926,799
  
Pre. Close: 10.82
Low: 10.88
Market Cap: 2,868(M)
Technical analysis
2025-04-17 4:51:18 PM
Short term     
Mid term     
Targets 6-month :  16.25 1-year :  18.54
Resists First :  13.91 Second :  15.87
Pivot price 12.63
Supports First :  10.75 Second :  8.94
MAs MA(5) :  11.09 MA(20) :  13.2
MA(100) :  14.92 MA(250) :  17.79
MACD MACD :  -1.1 Signal :  -0.9
%K %D K(14,3) :  4.4 D(3) :  4.6
RSI RSI(14): 31.8
52-week High :  23.1 Low :  10.75
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ OGN ] has closed above bottom band by 24.6%. Bollinger Bands are 182.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.24 - 11.3 11.3 - 11.36
Low: 10.71 - 10.8 10.8 - 10.87
Close: 11 - 11.12 11.12 - 11.23
Company Description

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Headline News

Sun, 20 Apr 2025
Cautious Hold Rating on Organon Amid Updated Financials and Market Conditions - TipRanks

Tue, 15 Apr 2025
Organon expands board with new director from Takeda - Investing.com

Tue, 15 Apr 2025
Takeda President Ramona Sequeira Joins Organon Board: Major Win for Women's Health Giant - Stock Titan

Tue, 15 Apr 2025
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Business Wire

Tue, 15 Apr 2025
Organon Earnings Alert: Q1 2025 Results Coming May 1 with $6M Milestone Expenses - Stock Titan

Tue, 15 Apr 2025
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - Business Wire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Shares Out 258 (M)
Shares Float 257 (M)
Held by Insiders 0.2 (%)
Held by Institutions 83.2 (%)
Shares Short 18,360 (K)
Shares Short P.Month 18,450 (K)
Stock Financials
EPS 3.32
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.83
Profit Margin 13.4 %
Operating Margin 18.7 %
Return on Assets (ttm) 7.3 %
Return on Equity (ttm) 429.8 %
Qtrly Rev. Growth -0.5 %
Gross Profit (p.s.) 14.42
Sales Per Share 24.81
EBITDA (p.s.) 6.82
Qtrly Earnings Growth -80.7 %
Operating Cash Flow 939 (M)
Levered Free Cash Flow 569 (M)
Stock Valuations
PE Ratio 3.33
PEG Ratio 0
Price to Book value 6.07
Price to Sales 0.44
Price to Cash Flow 3.05
Stock Dividends
Dividend 0.28
Forward Dividend 0
Dividend Yield 2.5%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android